Aligos Therapeutics Inc (ALGS)
$0.7931
+0.01
(+0.78%)▲
Insights on Aligos Therapeutics Inc
Decreasing Revenue
Revenue is down for the last 3 quarters, 6.88M → 2.68M (in $), with an average decrease of 35.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -18.04M → -27.89M (in $), with an average decrease of 54.6% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 63.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 341.5%
Performance
- $0.76$0.82$0.79
4.05%
Downside
Day's Volatility :7.56%
Upside
3.66%
- $0.54$1.38$0.79
31.8%
Downside
52 Weeks Volatility :60.96%
Upside
42.75%
Returns
| Period | Aligos Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 14.06% | -0.7% | 0.0% |
6 Months | 2.21% | 6.6% | 0.0% |
1 Year | -17.2% | 3.7% | -1.5% |
3 Years | -96.35% | 14.0% | -21.8% |
Highlights
Market Capitalization | 63.2M |
Book Value | $1.23 |
Earnings Per Share (EPS) | -1.36 |
Wall Street Target Price | 4.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -942.67% |
Return On Assets TTM | -36.64% |
Return On Equity TTM | -89.48% |
Revenue TTM | 15.5M |
Revenue Per Share TTM | 0.24 |
Quarterly Revenue Growth YOY | -24.2% |
Gross Profit TTM | -71.2M |
EBITDA | -85.8M |
Diluted Eps TTM | -1.36 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.83 |
EPS Estimate Next Year | -0.82 |
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Next Quarter | -0.27 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 404.35%
Technicals Summary
Sell
Neutral
Buy
Aligos Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Aligos Therapeutics Inc | -14.46% | 2.21% | -17.2% | -96.35% | -94.7% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Aligos Therapeutics Inc | NA | NA | NA | -0.83 | -0.89 | -0.37 | NA | 1.23 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Aligos Therapeutics Inc | Buy | $63.2M | -94.7% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Armistice Capital, LLC
9.10%EcoR1 Capital, LLC
8.51%Deep Track Capital, LP
8.13%Vivo Capital, LLC
4.72%TANG CAPITAL MANAGEMENT LLC
4.43%Altitude Crest Partners Inc
3.79%
Corporate Announcements
Aligos Therapeutics Inc Earnings
Aligos Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-ã agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.
Organization | Aligos Therapeutics Inc |
Employees | 66 |
CEO | Dr. Lawrence M. Blatt MBA, Ph.D. |
Industry | Health Technology |
